Sijibio Participates in NASSi...Promotes Key Products to Global Audience

CGBio recently announced on the 4th that it participated in the North American Spine Society International (NASSi) event held in Bangkok, Thailand, where it introduced its key pipeline products.

Visitors are viewing the CGBio booth set up at the North American Spine Society International (NASSi) event recently held in Bangkok, Thailand.
[Photo by CGBio]

At this NASSi event, CGBio showcased its major products in the bone, spine, and surgical fields, including the bone substitute materials ‘NOVOSIS’ and ‘BONGROS’, the temperature-responsive anti-adhesion agent ‘MEDICLORE’, and the next-generation height-expandable cage ‘Excender’.

NOVOSIS, Korea’s first bio-converged medical device, is a bone substitute composed of a hydroxyapatite carrier loaded with the bone morphogenetic protein 'rhBMP-2'. BONGROS is a bone substitute made of hydroxyapatite ceramic and serves as the carrier for NOVOSIS. The height-expandable cage Excender can expand in height after implantation to allow injection of bone substitute material into the empty space, and its shielding structure minimizes the possibility of loss of the injected bone substitute. MEDICLORE is a temperature-responsive anti-adhesion agent that exists as a liquid sol at room temperature and transforms into a highly viscous gel upon application inside the body due to body temperature; it also performs triple functions including hemostasis and antibacterial effects.

During the booth exhibition period, attendees and representatives from global companies from over 10 countries including the United States, Japan, and Taiwan visited the CGBio booth to engage in in-depth business discussions about CGBio’s integrated product portfolio, which encompasses all three essential elements for bone regeneration: Growth Factor, Scaffold, and Stem Cells. Additionally, a luncheon symposium was held to share the latest insights on endoscopic spine surgery, rhBMP-2, and height-expandable cages with global medical professionals. In particular, there was significant interest in NOVOMAX Fusion, a third-generation osteo-active bioglass ceramic cage that obtained approval in Japan last July following Europe and Australia, as well as in Excender and NOVOSIS, which are directly related to endoscopic spine surgery.

CGBio also operated an anatomical practice course during the conference. One medical professional who attended the course commented, “Excender was easy to use because it can be inserted into the body at a low height of 8 mm during bi-directional endoscopic spine surgery. It was attractive that it overcomes the limitations of fixed-height cages, where more than 30% of bone graft material is lost due to impact during cage insertion, by allowing injection of bone morphogenetic protein (rhBMP-2) and bone substitute material after height expansion, enabling faster and more effective bone fusion.”

Yoo Hyun-seung, CEO of CGBio, stated, “Participating in this NASSi was a valuable opportunity to understand the latest trends in spine and related medical technologies, introduce CGBio products directly to medical professionals who actually use them, and listen to frontline opinions. We will actively reflect the latest insights and feedback obtained this time in future product and technology development and do our best to present products that are truly necessary for patients and medical professionals.”

This content was produced with the assistance of AI translation services.